Pharmaceutical

Jolt Health Inc. Financing Update

VANCOUVER, BC / ACCESSWIRE / July 26, 2024 / Jolt Health Inc. ("JOLT" and or "the Company") (CSE:JOLT)(FSE:G1Q0) announced that…

1 year ago

KORU Medical Systems to Participate in the Canaccord Genuity 44th Annual Growth Conference

MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on the…

1 year ago

Specialty Enzymes Market to Surpass USD 10.4 Billion by 2034, Growing at a 6.4% CAGR: Digital Technologies and Automation Drive Efficiency and Cost Reduction | TMR

Growing consumer awareness of enzyme benefits fuels demand for enzyme-based products in various health and wellness sectors. WILMINGTON, Del., July…

1 year ago

Allarity Therapeutics Announces Postponement of Annual Stockholders Meeting

Boston (July 26, 2024)—Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to…

1 year ago

Silo Pharma to Present at H.C. Wainwright Annual Global Investment Conference

Presentation to feature Silo’s novel therapeutics for the underserved SARASOTA, FL, July 26, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc.…

1 year ago

TRxADE Health, Inc. Announces Business Combination with Scienture, Inc., in a Transaction Valued at $103 Million

Scienture, Inc., a private branded and specialty pharmaceutical company, entered into a business combination with TRxADE Health Inc., in an all-stock transaction…

1 year ago

GENFIT: Positive Opinion from EMA Committee for Ipsen’s Iqirvo® (elafibranor) in Primary Biliary Cholangitis

Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), July 26, 2024 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical…

1 year ago

Legend Biotech Announces Preliminary Results for the Six-Months Ended June 30, 2024

SOMERSET, N.J., July 26, 2024 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell…

1 year ago

Ipsen receives CHMP positive opinions for Iqirvo® (elafibranor) in Primary Biliary Cholangitis and Kayfanda® (odevixibat) in Alagille Syndrome, two rare cholestatic liver diseases

Ipsen receives CHMP positive opinions for Iqirvo® (elafibranor) in Primary Biliary Cholangitis and Kayfanda® (odevixibat) in Alagille Syndrome, two rare…

1 year ago

California Institute for Regenerative Medicine Awards Funding for CAR-T NXC-201 U.S. AL Amyloidosis Clinical Trial (NEXICART-2)

$8 million grant funds development of NXC-201 in relapsed/refractory AL AmyloidosisLOS ANGELES, CA, July 25, 2024 (GLOBE NEWSWIRE) -- Nexcella,…

1 year ago